ArticleThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation2020
Circulating NEDD9 is increased in pulmonary arterial hypertension: A multicenter, retrospective analysis.
Article in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- The NOTCH3 extracellular domain is a serum biomarker for pulmonary arterial hypertension.Nature medicine · 2026Article
- Protein biomarkers in pulmonary arterial hypertension: advances, clinical relevance, and translational challenges.Journal of translational medicine · 2025Review
- Pulmonary artery smooth muscle cell pyroptosis promotes the proliferation of PASMCs by paracrine IL‑1β and IL‑18 in monocrotaline‑induced pulmonary arterial hypertensive rats.Experimental and therapeutic medicine · 2024Article
- Circulating Biomarkers of Endothelial Dysfunction Associated With Ventilatory Ratio and Mortality in ARDS Resulting From SARS-CoV-2 Infection Treated With Antiinflammatory Therapies.CHEST critical care · 2024Article
- Mechanisms of Pulmonary Vasculopathy in Acute and Long-Term COVID-19: A Review.International journal of molecular sciences · 2024Review
- Plasma NEDD9 is increased following SARS-CoV-2 infection and associates with indices of pulmonary vascular dysfunction.Pulmonary circulation · 2024Article
- Characteristic disease defects in circulating endothelial cells isolated from patients with pulmonary arterial hypertension.PloS one · 2024Article
- Associations of Histamine Metabolites with Disease Severity and Mortality in Pulmonary Arterial Hypertension.Annals of the American Thoracic Society · 2023Article
- Therapeutic targeting of mineralocorticoid receptors in pulmonary hypertension: Insights from basic research.Frontiers in cardiovascular medicine · 2023Review
- Plasma Cell-Free DNA Predicts Survival and Maps Specific Sources of Injury in Pulmonary Arterial Hypertension.Circulation · 2022Article
- Human umbilical cord mesenchymal stem cell-derived treatment of severe pulmonary arterial hypertension.Nature cardiovascular research · 2022Article
- NEDD9 provides mechanistic insight into the coagulopathy of COVID-19.Pulmonary circulation · 2022Article
- Network medicine in Cardiovascular Research.Cardiovascular research · 2021Review
- Associations of Angiopoietins With Heart Failure Incidence and Severity.Journal of cardiac failure · 2021Article
- NEDD9, a Hypoxia-upregulated Mediator for Pathogenic Platelet-Endothelial Cell Interaction in Pulmonary Hypertension.American journal of respiratory and critical care medicine · 2021Article
- The Evolution of Risk Assessment in Pulmonary Arterial Hypertension.Methodist DeBakey cardiovascular journal · 2021Article
- Pulmonary Artery Smooth Muscle Cell Senescence Promotes the Proliferation of PASMCs by Paracrine IL-6 in Hypoxia-Induced Pulmonary Hypertension.Frontiers in physiology · 2021Article
- Pulmonary arterial hypertension: Cellular and molecular changes in the lung.Global cardiology science & practice · 2020Review
- Pulmonary arterial hypertension: Rationale for using multiple vs. single drug therapy.Global cardiology science & practice · 2020Review
- Pulmonary Arterial Hypertension in Graves' Disease: Role of Thyroid Autoimmunity and NEDD9.Indian journal of endocrinology and metabolismArticle
Corrections and comments
- Commented on by
Authors and funding
17 authors at 7 institutions in 1 country.
Funding
Abstract
backgroundPulmonary arterial hypertension (PAH) is a highly morbid disease characterized by elevated pulmonary vascular resistance (PVR) and pathogenic right ventricular remodeling. Endothelial expression of the prometastatic protein NEDD9 is increased in fibrotic PAH arterioles, and NEDD9 inhibition decreases PVR in experimental PAH. We hypothesized that circulating NEDD9 is increased in PAH and informs the clinical profile of patients.
methodsClinical data and plasma samples were analyzed retrospectively for 242 patients from 5 referral centers (2010-2017): PAH (n = 139; female 82%, 58 [48-67] years), non-PAH pulmonary hypertension (PH) (n = 54; female 56%, 63.4 ± 12.2 years), and dyspnea non-PH controls (n = 36; female 75%, 54.2 ± 14.0 years).
resultsCompared with controls, NEDD9 was increased in PAH by 1.82-fold (p < 0.0001). Elevated NEDD9 correlated with PVR in idiopathic PAH (ρ = 0.42, p < 0.0001, n = 54), connective tissue disease (CTD)-PAH (ρ = 0.53, p < 0.0001, n = 53), and congenital heart disease-PAH (ρ = 0.68, p < 0.0001, n = 10). In CTD-PAH, NEDD9 correlated with 6-minute walk distance (ρ = -0.35, p = 0.028, n = 39). In contrast to the PAH biomarker N-terminal pro-brain natriuretic peptide (n = 38), NEDD9 correlated inversely with exercise pulmonary artery wedge pressure and more strongly with right ventricular ejection fraction (ρ = -0.41, p = 0.006, n = 45) in a mixed population. The adjusted hazard ratio for lung transplant-free survival was 1.12 (95% confidence interval [CI], 1.02-1.22, p = 0.01) and 1.75 (95% CI, 1.12-2.73, p = 0.01) per 1 ng/ml and 5 ng/ml increase in plasma NEDD9, respectively, by Cox proportional hazard model.
conclusionsIn PAH, plasma NEDD9 is increased and associates with key prognostic variables. Prospective studies that include hard end points are warranted to validate NEDD9 as a novel PAH biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.